Allopurinol

Llanol®

Prescription Drug

Indication

• For the management of patients with signs and symptoms of primary and secondary gout (recurrent acute attacks, arthropathy, tophi, radiographic changes of gout, or associated uric acid nephrolithiasis);
• For the management of patients with leukemia, lymphoma and solid tumor malignancies who are undergoing chemotherapy expected to result in tumor lysis and subsequent elevations of serum and urinary uric acid concentrations. Allopurinol therapy should be discontinued when the potential for hyperuricemia is no longer present;
• For the management of patients with recurrent calcium oxalate renal calculi in males whose urinary urate excretion exceeds 800 mg daily and in females whose urinary urate excretion exceeds 750 mg daily. The use of allopurinol for this condition must be carefully evaluated initially and reevaluated periodically to determine that therapy with the drug is beneficial and outweighs the risks.

Dosage and Administration

For more information on safety, recaution and other information about this product, please see the Product Insert.